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BACKGROUND: Urinary biomarkers are needed to improve the care and reduce the cost of managing bladder cancer. Current
biomarkers struggle to identify both high and low-grade cancers due to differing molecular pathways. Changes in microRNA (miR)
expression are seen in urothelial carcinogenesis in a phenotype-specific manner. We hypothesised that urinary miRs reflecting
low- and high-grade pathways could detect bladder cancers and overcome differences in genetic events seen within the disease.
METHODS: We investigated urinary samples (n¼ 121) from patients with bladder cancer (n¼ 68) and age-matched controls (n¼ 53).
Fifteen miRs were quantified using real-time PCR.
RESULTS: We found that miR is stable within urinary cells despite adverse handling and detected differential expression of 10 miRs
from patients with cancer and controls (miRs 15a/15b/24-1/27b/100/135b/203/212/328/1224, ANOVA Po0.05). Individually,
miR-1224-3p had the best individual performance with specificity, positive and negative predictive values and concordance of 83%,
83%, 75% and 77%, respectively. The combination of miRs-135b/15b/1224-3p detected bladder cancer with a high sensitivity
(94.1%), sufficient specificity (51%) and was correct in 86% of patients (concordance).
CONCLUSION: The use of this panel in patients with haematuria would have found 94% of urothelial cell carcinoma, while reducing
cystoscopy rates by 26%. However, two invasive cancers (3%) would have been missed.
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Bladder cancer is the fifth commonest malignancy in the United
States with 70 530 new cases and 14 680 deaths in 2010 (Jemal et al,
2010). The majority of urothelial cell carcinoma (UCC) is low grade
and non-muscle invasive. These are managed by endoscopic
resection with intra-vesical chemotherapy, and have an excellent
prognosis. Approximately 1/3 of UCC is high-grade and arises
from carcinoma in-situ. High-grade UCC is an aggressive disease
that may be detected before or with muscle invasion. Despite
radical therapy the mortality from invasive UCC is a round 50%,
reflecting the late stage at diagnosis and a poor response to
chemotherapy (Schrier et al, 2004). The relapsing natural history
of UCC and the frequency of suggestive symptoms mean that many
patients undergo diagnostic or repeated surveillance endoscopic
inspection of their bladder. Consequently, bladder cancer is one of
the most-expensive human malignancies. Estimates suggest the
disease costs around $3.7 billion/per annum in the US and the
majority of this cost is spent on diagnosis and surveillance of
disease (Sangar et al, 2005; Avritscher et al, 2006).
A robust urinary biomarker to detect UCC would considerably
improve the care of patients with and reduce the cost of managing
bladder cancer. Urine cytology is the most used non-invasive urinary
test for UCC. It has a high specificity but a low sensitivity for UCC
and is poor at detecting low-grade tumours (Planz et al, 2005;
Carmack and Soloway 2006). Multiple molecular urinary biomarkers
have been investigated to date, but none are sufficiently robust to
enter clinical practice (Zwarthoff 2008). Many biomarkers fail as
they are unable to detect both low and high-grade UCC, which
are characterised by distinct molecular pathways and share few
molecular alterations (Catto et al, 2005, 2009, 2010). Biomarker
panels that assess molecular events characteristic of low- and
high-grade UCC improve the accuracy of urinary tests, but are
laborious (van Rhijn et al, 2003).
MicroRNAs (miRs) are short non-coding RNA molecules that
post-transcriptionally modulate protein expression (Catto et al,
2011). Alterations in miR expression appear important for
carcinogenesis (He et al, 2005; Voorhoeve et al, 2006) and those
with differential expression between normal urothelium and
UCC have recently been described (Catto et al, 2009; Dyrskjot
et al, 2009). Their expression varies with disease phenotype and
reflects genetic or epigenetic events within the low- and high-grade
UCC pathways (Dudziec et al, 2011). Here, we test the hypothesis
that urinary miR expression can detect bladder cancer. Urine
contains many nucleases, and assays to examine mRNA expression
often fail due to target degradation or require stringent pre-
laboratory handling of the urine sample. Short RNA molecules are
less prone to degradation than long polyadenylated mRNAs and
may be stabilized by secretion within exosomes (Valadi et al,
2007). Recently, urinary miR expression has been reported and
the upregulation of miRs-126/182/199a found to discriminate
patients with UCC from disease-free controls (Hanke et al, 2009).
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This combination identified up to 77% of UCC cases, despite a lack
of differential expression for any of these miRs in malignant and
normal urothelium (Catto et al, 2009). We hypothesise that
analysing the expression of miRs characteristic of high- and low-
grade UCC could improve the performance of a miR-based urinary
test for the disease.
MATERIALS AND METHODS
Patients and samples
We studied freshly voided urine samples obtained from 121
patients of the Department of Urology, Royal Hallamshire
Hospital, UK (Table 1). These included 68 patients with current
UCC (both new and recurrent tumours) and 53 age-matched
controls without a history of UCC. Controls included those
requiring cystoscopy for symptoms suggestive of UCC (e.g.
haematuria), those undergoing treatment of benign urinary
conditions and patients without urinary pathology. Most patients
with urinary symptoms, uropathology or haematuria underwent
cystoscopy (50/53, 94%). Around 100–150ml of urine was collected
from each patient before instrumentation or bladder tumour
removal. Tumours were classified using the 1973 WHO criteria by
a specialist uropathologist (SLM). Informed consent was obtained
from each patient and institutional ethics committee approval
gained before commencing the study.
Urine processing and RNA extraction
Freshly voided urine was stored at 4 oC for up to 4 h and then
centrifuged at 3392 g for 10min. The supernatant was removed and
the cell pellet washed twice in PBS before freezing at  80oC until
use. To determine miR stability in urine, we split 25 samples into
three fractions (50ml for each) and separately extracted RNA in
the form of two reference genes (RNU48 and RNU44) and three
miRs (15b/135b/1224-3p) from an immediately processed sample,
following three cycles of freeze-thawing ( 80 oC to room
temperature) and following storage at room temperature for
48 h. We also compared miR yield using matched samples
collected into an empty container and into one containing
50% volume RNase inhibitor. RNA was extracted from cell
pellets using the mirVana kit (Ambion, Austin, TX, USA)
according to the manufacturer’s protocol and measured using a
2100 Bioanalyzer (Agilent, Stockport, UK).
MiR detection
The expression of 15miRs was measured using real-time PCR.
We selected miRs including (i) those with differential expression
in malignant and normal urothelium, (ii) miRs with up- and
downregulation in UCC, (iii) miRs representative of all UCC
Table 1 Patients and tumours studied in this report
Controls UCC cases
n % n %
Gender
Male 35 66 53 78
Female 18 34 15 22
Age
Median 62 72
Average 58 71
Range 17–83 38–87
Haematuria 28 53
Urolithiasis 10 19
Urinary infection 6 11
BPH (TURP) 6 11
Other 3 6
Differentiation
Grade 1 15 22
Grade 2 21 31
Grade 3 32 47
Stage
pTa 33 49
pTis 4 6
pT1 4 6
pT2–4 27 40
Total 53 68
Abbreviations: BPH¼ benign prostatic hyperplasia; TURP¼ trans-urethral resection
of prostate; UCC¼ urothelial cell carcinoma. Various controls including circumcision
(1), pulmonary embolus (1), appendicitis (1).
*
*
*
*
40
20
30
Immediate Freeze-thaw Room-temp 48 h 
Ct
 v
al
ue
20
30
Benign
UCC
10
B
A
RNU 48 RNU 44 miR-15b miR-135b miR-1224
–10
0
10
60%
80%
100%
Fr
eq
ue
nc
y 
de
te
ct
ed
 
0%
20%
40%
m
iR
-2
03
m
iR
-2
1
m
iR
-2
7b
m
iR
-1
5b
m
iR
-1
35
b
m
iR
-1
5a
m
iR
-2
12
m
iR
-2
11
m
iR
-1
00
m
iR
-2
3b
m
iR
-3
28
m
iR
-1
22
4
m
iR
-2
4-
1
m
iR
-1
83
m
iR
-1
33
b
Av
er
ag
e 
ΔC
t
Figure 1 Detection of microRNA in urinary cell pellets. (A) The
expression (presented as Ct value) of RNU48 and RNU44 and selected
miRs in urine samples undergoing various processing protocols. *P-value
o0.001. (B) The relative expression (presented as the average DCt value)
and the frequency of detection for each miR analysed is shown. MiRs with
higher expression are detected more frequently and therefore make better
biomarkers.
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(miR-135b), of high-grade UCC (miR-21) and of low-grade UCC
(miRs-100/133b), (iv) miRs subject to epigenetic regulation (miRs-
212/328/1224-3p) and (v) those located in an epigenetic hotspot on
chromosome 9 (miRs-23b/24-1/27b: a chromosome commonly
deleted in UCC) (Dudziec et al, 2011). We included RNAs with low
and high cellular expression to estimate the necessary abundance
for analytical reliability. Quantitation was determined relative
to snoRNA’s, of which we evaluated RNU44 and RNU48.
Complementary DNA synthesis was performed using 1–350 ng
RNA, multiplex hairpin primers (Megaplex RT Primers, Applied
Biosystems, Warrington, UK), 100mM deoxynucleotide triphos-
phates, 25mM magnesium-chloride, 20Uml 1 RNase inhibitor,
nuclease-free water, buffer and Multiscribe Reverse Transcriptase
(Applied Biosystems). This reaction was subjected to 40 cycles of
16 oC for 2min, 42 oC for 1min and 50 oC for 1min, before heating
to 85 oC for 5min. We used a nested PCR approach to determine
cDNA concentration, as our starting RNA concentration was low.
Reverse transcribed cDNA (2.5 ml) was added to a commercially
mixed buffer, polymerase and dNTPs (Pre-Amp Mastermix,
Applied Biosystems), and mixed with nested primers (Megaplex
Pre-Amp primers, Applied Biosystems) and nuclease-free water.
This reaction was heated to 95 oC for 10min, 55 oC for 2min,
72 oC for 2min followed by 12 cycles of 95 oC for 15 s, 60 oC
for 15 s after which it was finally heated to 99.9 oC for 10min.
Real-time PCR was conducted using this nested cDNA product,
nuclease-free water, Mastermix (TaqMan Pre-Amp Mastermix,
Applied Biosystems) and individual miR primers and probes.
This reaction was analysed using an ABI 7900HT real-time
PCR system. Amplification plots were checked manually using
detection software (SDS Version. 2.2.1, Applied Biosystems) to
confirm the Ct value corresponded with the midpoint of
logarithmic amplification.
Statistical methods
Relative miR concentrations were calculated with respect to
reference snoRNAs (DCt¼Ct miRCt reference) and inter-class
fold changes computed using the 2-DDCt function (Schmittgen et al,
2008). Comparisons were performed using Chi squared and T-tests
or ANOVA tests, as appropriate. Concordance with diagnosis was
calculated as described by Harrell (Catto et al, 2009). Unsupervised
hierarchical clustering was performed using DCt values in Cluster
3.0 and visualised in Tree view (Eisen Lab, www.rana.lbl.gov).
RESULTS
Urinary miR collection, extraction and quantification
Before the sample collection we evaluated three aspects of miR
handling and quantification. Firstly, we investigated the use of an
RNase inhibitor. We found urinary miR yields were no different
with or without the use of RNase inhibition (data not shown) and
so collected samples into empty universal containers. Secondly, we
subjected matching fractions from 25 freshly-frozen and thawed
urine samples to (i) immediate processing, (ii) storage at room
temperature for 48 h and (iii) three cycles of freeze-thawing. No
statistical difference in yield was shown for both the reference genes
RNU48 and RNU44, and miRs-15b/-135b/-1224-3p between urine
samples that were immediately processed and those that were stored in
room temperature for 48h before extraction (Figure 1A). However,
freeze-thawing did reduce yields for several RNAs when compared
with immediate processing. We used immediate processing for the
samples in this report. Thirdly, we compared two snoRNAs to identify
the best reference molecule for relative miR quantification. RNU48 was
detected in all cases, with a higher and less variable expression
Table 2 MicroRNA expression in urinary samples from patients with bladder cancer and controls
miR detected Expression (DCt)
n %
Chi sq
P-value Average s.d.
Fold change
with UCC
ANOVA
P-value
Concordance
for UCC Sen% Spec% PPV% NPV%
miR-15a Benign 50 94.3 6.35 4.14
UCC 58 85.3 0.03* 10.7 7.23 0.05 o0.001* 0.59 51.7 72.0 68.2 56.3
miR-15b Benign 48 90.6 3.29 3.36
UCC 59 86.8 0.4 8.21 5.8 0.03 o0.001* 0.71 67.8 81.3 81.6 67.2
miR-21 Benign 48 90.6 5.25 7.29
UCC 58 85.3 0.26 6.08 6.58 0.56 0.5 0.51 46.6 56.3 56.3 46.6
miR-23b Benign 41 77.4 15.42 5.12
UCC 21 30.9 o0.001* 17.85 5.84 0.19 0.097 0.62 57.1 65.9 46.2 75.0
miR-24-1 Benign 41 77.4 19.12 5.35
UCC 51 75.0 o0.001* 21.1 4.05 0.18 0.05* 0.64 60.0 58.5 63.8 54.5
miR-27b Benign 53 100 3.33 2.76
UCC 65 95.6 o0.001* 7.39 3.76 0.06 o0.001* 0.67 60.3 81.1 79.2 63.2
miR-100 Benign 47 88.7 8.96 5.83
UCC 48 70.6 0.01* 15.81 8.97 0.01 o0.001* 0.7 60.4 78.7 74.4 66.1
miR-133b Benign 5 9.4 23.9 7.65
UCC 7 10.3 0.87 24.22 6.82 0.8 0.9 0.73 85.7 60.0 75.0 75.0
miR-135b Benign 43 81.1 13.64 5.27
UCC 59 86.8 0.28 8.56 4.3 33.82 o0.001* 0.8 71.2 74.4 79.2 65.3
miR-183 Benign 32 60.4 21.36 6.1
UCC 19 27.9 o0.001* 21.87 6.96 0.7 0.8 0.51 52.6 50.0 38.5 64.0
miR-203 Benign 50 94.3 -1.68 2.57
UCC 62 91.2 0.21 0.19 4.56 0.27 0.01* 0.66 66.1 66.0 70.7 61.1
miR-211 Benign 48 90.6 17.5 7.59
UCC 28 41.2 o0.001* 15.3 10.86 4.59 0.3 0.59 46.4 41.7 31.7 57.1
miR-212 Benign 50 94.3 12.37 5.76
UCC 62 91.2 0.57 14.94 5.18 0.16 0.012* 0.59 54.2 64.0 64.0 54.2
miR-328 Benign 53 100 10.6 3.54
UCC 58 85.3 o0.001* 18.23 7.97 0.005 o0.001* 0.71 55.4 86.8 81.6 64.8
miR-1224 Benign 51 96.2 15.23 3.73
UCC 61 89.7 o0.001* 20.66 5.66 0.02 o0.001* 0.78 75.9 82.4 83.0 75.0
Abbreviations: ANOVA¼ analysis of variance; miR¼microRNA; NPV¼ negative predictor value; PPV¼ positive predictor value; Sen¼ sensitivity; Spec¼ specificity;
UCC¼ urothelial cell carcinoma. *Statistical significance, P-value o0.05.
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(n¼ 121 (100%), Ct average±s.d.: 20.8±4.3) than RNU44 (n¼ 114
(94%), Ct 28.7±6.45). We chose RNU48 as the reference RNA.
Urinary miR expression in patients with bladder cancer
and controls
Expression of miR varied by 30-million-fold from the lowest
(miR-133b) to highest (miR-203) (DDCt¼  24.8, Figure 1B).
MicroRNAs with low concentration were less frequently detected
than those with high expression (10% vs 93%, respectively, Chi sq
Po0.001). Reliable detection (e.g. in 480% of samples) was seen
in miRs with a 9000 fold change in expression (miR-203 to miR-
100, DDCt¼  13.1, fold change¼ 8964). The miRs were detected
more frequently in urinary samples from benign than UCC cases
(Table 2). This difference reached significance for nine miRs
(miRs-15a/15b/24-1/27-b/100/203/212/328/1224 (Chi Sq Po0.03)).
Quantification revealed differences in expression for 10 miRs
between benign and malignant cases (ANOVA P o0.05). Patients
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Figure 2 Expression of microRNA in urinary cell pellets. Unsupervised hierarchical clustering using either (A) eight or (B) three selected miRs identifies
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with UCC had lower expression of miRs-15a/15b/24-1/27b/100/
203/212/328/1224-3p and higher expression of miR-135b, when
compared with controls.
Non-invasive diagnosis of bladder cancer
We calculated the diagnostic performance for UCC of the
differentially expressed miRs, using expression dichotomized
around the mean DCt (Figure 2). The accuracy of individual miRs
varied from 0.61 to 0.80 for UCC (Concordance indices, Table 2).
The sensitivity and specificity for UCC ranged from 51.7% (miR-
15a) to 75.9% (miR-1224-3p) and 58.5% (miR-24-1) to 86.8%
(miRs-212/328), respectively. MiR-1224-3p had the best individual
performance with specificity, positive and negative predictive
values of 83%, 83% and 75%, respectively. The combination of
miRs improved their diagnostic performance. The best concor-
dance for UCC was achieved using either a combination of eight
(C-index 0.86, miRs-15a/15b/27b/100/135b/203/212/1224-3p) or
three miRs (C-index 0.86, miRs-15b/135b/1224-3p, Figure 3). The
three miR combination appeared most sensitive for UCC (94.1%),
but had a low specificity (51%). Clustering using these selected
panels separated the samples into two large cohorts representing
mostly benign or UCC cases, and a small intermediate group
(n¼ 23, 19%; Figure 3).
DISCUSSION
Here, we have shown that urinary miRs appear promising
biomarkers for the detection of bladder cancer. When compared
with previously analysed candidates, their stability and flexibility
in measurement makes them appealing diagnostic targets. By
incorporating miRs with known changes in UCC, we found it
possible to design a panel with a high sensitivity for the disease. Of
note, when implementing a urinary test to stratify the need for
cystoscopy, it is sensitivity (to reduce false negative tests) that is
more important than specificity.
Firstly, the expression of urinary miRs appears stable ex vivo
when stored at room temperature. This stability may be due to
their small size that makes them less likely to fragment than large
RNAs, their lack of polyadenylated tail that nucleases target
(Guhaniyogi and Brewer 2001), or that they are secreted within
exosomes, which protect RNA from degradation (Valadi et al,
2007). Exogenously administered free miR undergoes rapid
clearance in biological fluids, suggesting the inclusion within an
exosome is critical for protection (Mitchell et al, 2008). This
ex vivo stability is important in clinical use, where transit to
laboratory of biological samples is inconsistent.
Secondly, it is possible to multiplex miR assays into custom
combinations to detect specific diseases. With this in mind, we
selected 15 miRs whose expression is relatively UCC-specific and
were representative of the low- and high-grade tumour pathways
(Catto et al, 2009, 2011). We included those with functional
roles in urothelial carcinogenesis, such as growth promotion
through FGFR3 targeting (miR-100) and apoptosis avoidance/cell
cycle regulation (miR-21), and those with epigenetic regulation
(e.g. miR-1224-3p). We found that low abundance miRs are not
reliably detected in urinary cells, even though their expression
may be UCC-specific (such as miR-133b). We identified 13 miRs
whose urinary presence or expression was abnormal in the UCC
patients when compared with controls. Of these, several had
alterations that matched primary tumours and was in keeping
with their carcinogenic roles (e.g. miR-135b and miR-100).
Potentially the most useful was miR-135b, as this was one of only
two upregulated species and is one of the most overexpressed
miRs UCC tissue (Catto et al, 2009). Similar observations are
detailed in colorectal cancer, where miRs-135b/135a are implicated
in APC silencing (Nagel et al, 2008). In UCC, predicted targets
for miR-135b include LATS2 (Catto et al, 2009) and Annexin A7.
When combined, we found three miRs with a high sensitivity for
UCC (miRs-135b/15b/1224-3p (94.1%)). Implementing this panel
in our cohort, would have avoided 31 (26%) cystocopies, but
missed four cancers. Of these, two were invasive and two low-grade
non-invasive UCC (thus, the risk of missing a significant tumour
was 2/63 (3%)).
Our experiments revealed that most urinary miRs are down-
regulated in the presence of UCC, when compared with controls.
This was a surprising outcome as we selected several that are
upregulated in UCC. The RNA within urinary cells and exosomes
may be derived from bladder tumours, from the normal
urothelium or be filtered from the glomerulus and secreted by
the renal tubules (Johnstone and Holzman 2006). As such the
changes we observed may reflect events within the urothelium or
the host’s response to disease, masking tumour-specific miR
changes.
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Recent work has reported the use of three miRs in the detection
of UCC (Hanke et al, 2009). The authors screened pooled urine
samples from healthy controls, controls with urinary infections,
patients with low-grade UCC and from patients with high-grade
UCC for the expression of 157 miRs. They found miRs-126/152/
199a were overrepresented in the urine from UCC cases and
analysed these in a further 47 samples (n¼ 11 controls and n¼ 36
patients with UCC). In isolation or combination the three miR
panel detected up to 77% of UCC cases (sensitivity 55%, specificity
82%). However, either of their selected miRs was altered in the
UCC specimens we previously analysed (Catto et al, 2009). Of note,
in this report miR expression was normalised against miR-152.
We found miR-152 had reduced expression in UCC (fivefold lower
than normal urothelium) and thus may be a poor reference target.
MiR-152 is located within a CpG island on Chromosome 17 and it’s
silencing by hypermethylation has been observed in breast cancer
(Lehmann et al, 2008).
To conclude, urinary miRs appear promising biomarkers for
bladder cancer. We identified a panel of three miRs whose use
would have found 94% of UCC, while reducing cystoscopy rates by
26% in patients with haematuria. However, this panel would have
missed two invasive cancers (3%).
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